Alzheimer's DiseasePhase 2NCT02880956
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
A Phase 2 study testing ABBV-8E12 in people with Alzheimer's Disease, run by AbbVie at 68 sites in 11 countries.
Trial summary
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD). Read more about this study
- Who is it for?
- Ages 55 to 85 years
- Conditions the study is for
- Alzheimer's Disease
- What is being tested?
- ABBV-8E12
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 453 participants
- Where
- 68 sitesin 11 countries
- Study dates
- 26 Jan 2017to 28 Jul 2021
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject who meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) clinical criteria for mild cognitive impairment or probable AD, and have:
- Clinical Dementia Rating (CDR)-Global Score of 0.5
- Mini-Mental State Examination (MMSE) score of 22 to 30, inclusive
- Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory Index (RBANS - DMI) score of 85 or lower
- Subject has a positive amyloid positron emission tomography (PET) scan.
- Subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4.
- The subject has an identified, reliable, study partner (e.g., family member).
- If using medications to treat symptoms related to AD, doses must be stable for at least 12 weeks prior to randomization.
Who cannot join
- Subject has any contraindications or inability to tolerate brain magnetic resonance imaging (MRI), PET scans or lumbar puncture.
- Subject has evidence of any other clinically significant neurological disorder other than early AD.
- In the opinion of the investigator, the subject has any clinically significant or uncontrolled medical or psychiatric illness, or has had an infection requiring medical intervention in the past 30 days.
- Subject has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or required intervention for any of these conditions within 6 months of Screening.
Trial locations and contacts
68 sites in 11 countries.
68 sites in 11 countries
United States38 sites
Integrated Neurology Services /ID# 154863
Alexandria, Virginia, 22310
Emory Midtown Infectious Disease Clinic /ID# 151492
Atlanta, Georgia, 30322
Atlanta Center for Medical Research /ID# 151550
Atlanta, Georgia, 30331
Johns Hopkins Bayview Med Cnt /ID# 151893
Baltimore, Maryland, 21224
Massachusetts General Hospital /ID# 151770
Boston, Massachusetts, 02114
Brigham and Women's Physicians /ID# 151882
Boston, Massachusetts, 02115
Great Lakes Clinical Trials /ID# 152754
Chicago, Illinois, 60640
Kerwin Research Center /ID# 147815
Dallas, Texas, 75231-4316
NeuroStudies.net, LLC /ID# 152746
Decatur, Georgia, 30030
Brain Matters Research /ID# 147796
Delray Beach, Florida, 33445
Duke Cancer Center /ID# 147828
Durham, North Carolina, 27710-3000
University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554
Fairway, Kansas, 66205
Neuropsychiatric Research Center of Southwest Florida /ID# 162332
Fort Myers, Florida, 33912
Hattiesburg Clinic /ID# 202388
Hattiesburg, Mississippi, 39401
Houston Methodist Hospital /ID# 154810
Houston, Texas, 77030
McGovern Medical School /ID# 204860
Houston, Texas, 77054
Indiana University /ID# 151861
Indianapolis, Indiana, 46202
Irvine Clinical Research /ID# 162331
Irvine, California, 92614
Mayo Clinic /ID# 151236
Jacksonville, Florida, 32224
Ucsd /Id# 152467
La Jolla, California, 92037
Scott Research Inc. /ID# 151880
Laurelton, New York, 11413
University of Kentucky Chandler Medical Center /ID# 152753
Lexington, Kentucky, 40536
Vanderbilt University Medical Center /ID# 154547
Nashville, Tennessee, 37232-0011
North Shore University Hospital /ID# 151632
New Hyde Park, New York, 11040
Synexus Clinical Research US, Inc. /ID# 147804
Orlando, Florida, 32806-1044
Advocate Lutheran General Hospital /ID# 152052
Park Ridge, Illinois, 60068
Banner University of Arizona Medical Center Phoenix /ID# 151536
Phoenix, Arizona, 85006
Keystone Clinical Studies LLC /ID# 202305
Plymouth Meeting, Pennsylvania, 19462
Oregon Health and Science University /ID# 151690
Portland, Oregon, 97239
Princeton Medical Institute /ID# 152934
Princeton, New Jersey, 08540
Rhode Island Hospital /ID# 151538
Providence, Rhode Island, 02903
University of Utah /ID# 151858
Salt Lake City, Utah, 84112-5500
Ray Dolby Brain Health Center /ID# 154965
San Francisco, California, 94113
Univ California, San Francisco /ID# 152053
San Francisco, California, 94143-2204
Southern IL Univ School of Med /ID# 151769
Springfield, Illinois, 62702
Banner Sun Health Res Inst /ID# 151895
Sun City, Arizona, 85351
University of South Florida /ID# 151890
Tampa, Florida, 33612
Synexus Clinical Research US, Inc /ID# 151633
The Villages, Florida, 32162-7116
Italy7 sites
IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli /ID# 152395
Brescia, 25125
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 152401
Milan, 20122
ASST Grande Ospedale Metropolitano Niguarda /ID# 152391
Milan, 20162
AOU di Modena /ID# 152394
Modena, Emilia-Romagna, 41126
Azienda Ospedaliera di Perugia /ID# 152397
Perugia, Umbria, 06129
Policlinico Agostino Gemelli /ID# 152396
Rome, Lazio, 00168
Duplicate_AOU Policlinico Umberto I /ID# 163144
Rome, Lazio, 00185
Australia6 sites
The Kinghorn Cancer Centre /ID# 152632
Darlinghurst, New South Wales, 2010
Austin Health /ID# 152637
Heidelberg, Victoria, 3084
Australian Alzheimer's Res Fou /ID# 152634
Nedlands, Western Australia, 6009
The Royal Melbourne Hospital /ID# 202633
Parkville, Victoria, 3050
Griffith University /ID# 152635
Southport, Queensland, 4222
Neurodegenerative Disorders Research /ID# 152826
West Perth, Western Australia, 6005
Spain5 sites
Fundacio ACE /ID# 152643
Barcelona, 08028
Hospital Clinic de Barcelona /ID# 152646
Barcelona, 08036
Fundacion CITA Alzheimer Fundazioa /ID# 152645
Donostia / San Sebastian, Basque Country, 20009
Hospital Clinico Universitario San Carlos /ID# 153703
Madrid, 28040
Hospital Universitario 12 de Octubre /ID# 152647
Madrid, 28041
Belgium3 sites
Universitair Ziekenhuis Leuven /ID# 152642
Leuven, Vlaams-Brabant, 3000
Groupe Sante CHC - Clinique du MontLegia /ID# 152846
Liège, 4000
UCL Saint-Luc /ID# 152847
Woluwe-Saint-Lambert, Brussels Capital, 1200
Canada2 sites
Parkwood Institute /ID# 164204
London, Ontario, N6C 0A7
Toronto Memory Program /ID# 147863
Toronto, Ontario, M3B 2S7
Finland2 sites
Ita-Suomen Yliopisto /ID# 152959
Kuopio, 70210
Clinical Research Services Turku /ID# 152845
Turku, Southwest Finland, 20520
Sweden2 sites
Sahlgrenska University Hospital Molndal /ID# 154465
Mölndal, Västra Götaland County, 431 80
Karolinska University Hospital Huddinge /ID# 156705
Stockholm, Stockholm County, 171 77
Netherlands1 site
Universitair Medisch Centrum Utrecht /ID# 163576
Utrecht, 3584 CX
About this study
Official title: A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Conditions
- Alzheimer's Disease
- Being tested
- ABBV-8E12, placebo for ABBV-8E12
- Keywords
- Early Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Alzheimer's Disease (AD), Tau, Early dementia, Tauopathies, AD, Neurodegenerative diseases, Memory loss, Nervous system diseases
- Medical subject headings
- Alzheimer Disease, Cognitive Dysfunction, Pick Disease of the Brain, Dementia, Tauopathies, Neurodegenerative Diseases, Memory Disorders, Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ABBV-8E12Drug
Also called Tilavonemab
ABBV-8E12 solution for IV infusion
placebo for ABBV-8E12Drug
placebo solution for intravenous (IV) infusion
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo for ABBV-8E12 every 4 weeks for 96 weeks Receives: Drug: placebo for ABBV-8E12 |
| ABBV-8E12 300 mg | Experimental | ABBV-8E12 300 mg every 4 weeks for 96 weeks Receives: Drug: ABBV-8E12 |
| ABBV-8E12 1000 mg | Experimental | ABBV-8E12 1000 mg every 4 weeks for 96 weeks Receives: Drug: ABBV-8E12 |
| ABBV-8E12 2000 mg | Experimental | ABBV-8E12 2000 mg every 4 weeks for 96 weeks Receives: Drug: ABBV-8E12 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline Over Time in CDR-SB Score
The CDR-SB is a numeric scale used to quantify the severity of symptoms of dementia. A qualified health professional assesses a participant's cognitive and functional performance in 6 areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The CDR scale gives a score from 0 to 3 for each of the 6 areas, with a lower value being desirable. The sum of these 6 areas, the CDR-SB score, can range from 0 to 18, with a lower value being desirable.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event (AE) that began on or after the first study drug dose date and no more than 20 weeks after the last dose of study drug. An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. Serious AEs (SAEs) were defined as an event that results in death, is life-threatening, results in hospitalization or prolongs hospitalization, is a congenital abnormality, results in persistent or significant disability/incapacity, or is an important medical event. Events were rated in severity as mild, moderate, or severe, and were categorized as having a reasonable possibility or no reasonable possibility of relationship to study drug.
Measured: From first dose of study drug up to last dose of study drug plus 20 weeks (up to Week 112)
Secondary outcomes (45)
Maximum Observed Serum Concentration (Cmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Time to Cmax (Tmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Serum Concentration at the End of a Dose Interval (Ctrough) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Half-Life (T1/2) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Harmonic mean is presented in the data table.
Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Area Under the Concentration-Time Curve From Dosing (Time 0) to Day 28 (AUC0-28) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
- The AUC0-28 for Dose 1 included the following timepoints: pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 5, Day 15 and Day 29 (trough level before Dose 2).
- The AUC0-28 for Dose 4 included the following timepoints: Day 85 pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 89, Day 99 and Day 113 (trough level before Dose 5).
Measured: Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.
Cmax/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
AUC0-28/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
- The AUC0-28/dose for Dose 1 included the following timepoints: pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 5, Day 15 and Day 29 (trough level before Dose 2).
- The AUC0-28/dose for Dose 4 included the following timepoints: Day 85 pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 89, Day 99 and Day 113 (trough level before Dose 5).
Measured: Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.
Change From Baseline Over Time in Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14) Total Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in mild cognitive impairment (MCI) patients. The Total Score of the ADAS-Cog-14 ranges from 0 to 90, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Comprehension of Spoken Language Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Comprehension of Spoken Language score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Constructional Praxis Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Constructional Praxis Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Commands Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Commands Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Delayed Word Recall Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Delayed Word Recall Score of the ADAS-Cog-14 ranges from 0 to 10, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Ideational Praxis Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Ideational Praxis Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Maze Task Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Maze Task Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Number Cancellation Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Number Cancellation Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Naming Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Naming Score of the ADAS-Cog-14 ranges from 0 to 5 with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Orientation Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Orientation Score of the ADAS-Cog-14 ranges from 0 to 8, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Word Recall - Number of Words Not Recalled Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Word Recall - Number of Words Not Recalled Score of the ADAS-Cog-14 ranges from 0 to 10, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Remember Word Recognition Instructions Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Remember Word Recognition Instructions Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Spoken Language Ability Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Spoken Language Ability Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Word Find Difficulty Spontaneous Speech Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Word Find Difficulty Spontaneous Speech Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Word Recognition Score
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Word Recognition Score of the ADAS-Cog-14 ranges from 0 to 12, with a higher score representing greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in Functional Activities Questionnaire (FAQ) Score
The FAQ measures level of assistance (functional disability) needed for carrying out instrumental activities in daily living (iADLs). The FAQ score ranges from 0 - 30 and consists of 10 items (each scored from 0 - 3), which measure a specific iADL in the past 4-weeks: [1) writing checks, paying bills, keeping financial records; 2) assembling tax or business records; 3) shopping alone; 4) playing a game of skill; 5) making coffee or tea; 6) preparing a balanced meal; 7) keeping track of current events; 8) attending to and understanding a television program, book, or magazine; 9) remembering appointments, family occasions, medications; and 10) traveling out of the neighborhood]. Performance in each category is rated from 0 - 3 as follows: 0 - normal; 1 - has difficulty, but does by self; 2 - requires assistance; or 3 - dependent. The FAQ was administered by a trained interviewer. Higher scores indicate a greater requirement of assistance.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI) General Condition Score
The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning. Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.
Measured: Baseline, Week 48, Week 96
Change From Baseline Over Time in ADCS-CGIC-MCI Cognition Score
The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning. Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.
Measured: Baseline, Week 48, Week 96
Change From Baseline Over Time in ADCS-CGIC-MCI Behavior Score
The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning. Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.
Measured: Baseline, Week 48, Week 96
Change From Baseline Over Time in ADCS-CGIC-MCI Functional Abilities Score
The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning (functional abilities). Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.
Measured: Baseline, Week 48, Week 96
Change From Baseline Over Time in University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief) - Total Score
The UPSA-Brief is a performance-based instrument which uses a series of tasks and roleplay scenarios to evaluate a person's functional capacity in two areas of basic living skills (i.e., financial skills and communication skills). Scores range from 0 to 100; a higher score of the UPSA-Brief is desirable.
Measured: Baseline, Week 48, Week 96
Change From Baseline Over Time in 24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients With Mild Cognitive Impairment (ADCS-MCI-ADL-24) Total Score
The ADCS-MCI-ADL-24 is a 24-item, study partner-based assessment of activities of daily living designed specifically for AD patients and is completed by a trained rater. The scale assesses functional activities such as cooking, household chores, shopping, keeping appointments, social interactions and hobbies. Items are assessed according to whether they were performed in the past 4 weeks and, if so, some items are further assessed as to whether they were performed independently, with supervision, or with physical help. Scores on the ADCS-ADL-MCI range from 0 to 69, where higher score indicates greater capability to carry out activities of daily living.
Measured: Baseline, Week 48, Week 96
Change From Baseline Over Time in Repeatable Battery for Assessment of Neuropsychological Status (RBANS) - Total Scale Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. Total score can range from 40 to 160 with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Coding Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Coding Total Score of the RBANS ranges from 0 to 89, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Digit Span Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Digit Span Total Score of the RBANS ranges from 0 to 8, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Figure Copy Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Figure Copy Total Score of the RBANS ranges from 0 to 20, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Figure Recall Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Figure Recall Total Score of the RBANS ranges from 0 to 18, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - List Recognition Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The List Recognition Total Score of the RBANS ranges from 0 to 20, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - List Learning Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The List Learning Total Score of the RBANS ranges from 0 to 40, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Line Orientation Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Line Orientation Total Score of the RBANS ranges from 0 to 20, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - List Recall Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The List Recall Total Score of the RBANS ranges from 0 to 10, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Picture Naming Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Picture Naming Total Score of the RBANS ranges from 0 to 10, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Semantic Fluency Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Semantic Fluency Total Score of the RBANS ranges from 0 to 40, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Story Memory Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Story Memory Total Score of the RBANS ranges from 0 to 24, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Story Recall Total Score
The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Story Recall Total Score of the RBANS ranges from 0 to 12, with a higher score representing a better outcome.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in Mini-Mental State Examination (MMSE) Total Score
The MMSE is a brief, 30-point questionnaire, administered by a trained rater, which provides a quantitative measure of cognitive status in adults and is widely used to screen for cognitive impairment and to estimate the severity of cognitive impairment at a given point in time in AD participants. The MMSE ranges from 0 to 30, with lower scores indicating greater impairment.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in Neuropsychiatry Inventory (NPI) Total Score
The NPI is used to assess changes in the participant's behavior that occurred in a defined period of time (4 weeks). The NPI assesses 12 behavioral domains on the dimensions of frequency and severity. Frequency is rated on a scale where 0 = absent, 1 = occasionally, 2 = often, 3 = frequently, 4 = very frequently. Severity is rated on a scale where 0 = absent, 1 = mild, 2 = moderate, 3 = severe. For each of the domains, 3 scores are obtained: frequency, severity, and total (product of frequency and severity; ranges from 0 to 12, with a lower score desirable). A total NPI score can be calculated by summing the domain total scores. Total Score ranges from 0 to 144 with a lower score desirable.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in Alzheimer's Disease Composite Score (ADCOMS) Score
ADCOMS score is a composite score which is a weighted linear combination of the selected individual scale items from ADAS-Cog-14 (see description in Outcome Measure 10) , MMSE (see description in Outcome Measure 45), and CDR-SB (see description in Outcome Measure 1) scales. The ADCOMS score ranges from 0 to 1.97, with a lower score desirable.
Measured: Baseline, Week 24, Week 48, Week 72, Week 96
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2016 (estimated)
- Study start26 Jan 2017
- Primary completion30 Mar 2021
- Study completion28 Jul 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 453 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02880956
- Sponsor's protocol ID
- M15-566
- Other IDs
- 2016-001634-10, 2016
- Status last verified
- Aug 2022
- First submitted
- 24 Aug 2016
- Last updated
- 26 Aug 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
- Expanded access
- Available
Publications
Wang D, Florian H, Lynch SY, Robieson W, Zhuang R, Kusiak C, Ross JL, Walsh JR, Graff O. Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease. Alzheimers Dement (N Y). 2025 Nov 22;11(4):e70181. doi: 10.1002/trc2.70181. eCollection 2025 Oct-Dec.
PubMed 41281734
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT02880956
- Acronym / sponsor ID
- M15-566
- Conditions
- Alzheimer's Disease
- Keywords
- Early Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Alzheimer's Disease (AD), Tau, Early dementia, Tauopathies, AD, Neurodegenerative diseases
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 453 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 26 Jan 2017 (actual)
- Primary completion
- 30 Mar 2021 (actual)
- Study completion
- 28 Jul 2021 (actual)
- First posted
- 26 Aug 2016 (estimated)
- Results
- Posted 26 Aug 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: placebo for ABBV-8E12Placebo for ABBV-8E12 every 4 weeks for 96 weeks |
| ABBV-8E12 300 mg | Experimental | Drug: ABBV-8E12ABBV-8E12 300 mg every 4 weeks for 96 weeks |
| ABBV-8E12 1000 mg | Experimental | Drug: ABBV-8E12ABBV-8E12 1000 mg every 4 weeks for 96 weeks |
| ABBV-8E12 2000 mg | Experimental | Drug: ABBV-8E12ABBV-8E12 2000 mg every 4 weeks for 96 weeks |
Who may qualify
- Ages
- 55 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Subject who meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) clinical criteria for mild cognitive impairment or probable AD, and have:
- Subject has a positive amyloid positron emission tomography (PET) scan.
- Subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4.
- The subject has an identified, reliable, study partner (e.g., family member).
- If using medications to treat symptoms related to AD, doses must be stable for at least 12 weeks prior to randomization.
Key exclusion criteria (4 listed)
- Subject has any contraindications or inability to tolerate brain magnetic resonance imaging (MRI), PET scans or lumbar puncture.
- Subject has evidence of any other clinically significant neurological disorder other than early AD.
- In the opinion of the investigator, the subject has any clinically significant or uncontrolled medical or psychiatric illness, or has had an infection requiring medical intervention in the past 30 days.
- Subject has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or required intervention for any of these conditions within 6 months of Screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ABBV-8E12Also: TilavonemabABBV-8E12 solution for IV infusion | Drug | ABBV-8E12 1000 mg, ABBV-8E12 2000 mg, ABBV-8E12 300 mg |
| placebo for ABBV-8E12placebo solution for intravenous (IV) infusion | Drug | Placebo |
Primary outcome
Change From Baseline Over Time in CDR-SB Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
The CDR-SB is a numeric scale used to quantify the severity of symptoms of dementia. A qualified health professional assesses a participant's cognitive and functional performance in 6 areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The CDR scale gives a score from 0 to 3 for each of the 6 areas, with a lower value being desirable. The sum of these 6 areas, the CDR-SB score, can range from 0 to 18, with a lower value being desirable.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: From first dose of study drug up to last dose of study drug plus 20 weeks (up to Week 112)
A TEAE was defined as an adverse event (AE) that began on or after the first study drug dose date and no more than 20 weeks after the last dose of study drug. An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. Serious AEs (SAEs) were defined as an event that results in death, is life-threatening, results in hospitalization or prolongs hospitalization, is a congenital abnormality, results in persistent or significant disability/incapacity, or is an important medical event. Events were rated in severity as mild, moderate, or severe, and were categorized as having a reasonable possibility or no reasonable possibility of relationship to study drug.
45 secondary outcomes
Maximum Observed Serum Concentration (Cmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Time frame: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Time to Cmax (Tmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Time frame: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Serum Concentration at the End of a Dose Interval (Ctrough) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Time frame: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Half-Life (T1/2) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Time frame: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
Area Under the Concentration-Time Curve From Dosing (Time 0) to Day 28 (AUC0-28) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Time frame: Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.
Cmax/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Time frame: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.
AUC0-28/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses
Time frame: Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.
Change From Baseline Over Time in Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14) Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Comprehension of Spoken Language Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Constructional Praxis Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Commands Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Delayed Word Recall Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Ideational Praxis Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Maze Task Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Number Cancellation Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Naming Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Orientation Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Word Recall - Number of Words Not Recalled Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Remember Word Recognition Instructions Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Spoken Language Ability Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Word Find Difficulty Spontaneous Speech Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in ADAS-Cog-14 Word Recognition Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in Functional Activities Questionnaire (FAQ) Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI) General Condition Score
Time frame: Baseline, Week 48, Week 96
Change From Baseline Over Time in ADCS-CGIC-MCI Cognition Score
Time frame: Baseline, Week 48, Week 96
Change From Baseline Over Time in ADCS-CGIC-MCI Behavior Score
Time frame: Baseline, Week 48, Week 96
Change From Baseline Over Time in ADCS-CGIC-MCI Functional Abilities Score
Time frame: Baseline, Week 48, Week 96
Change From Baseline Over Time in University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief) - Total Score
Time frame: Baseline, Week 48, Week 96
Change From Baseline Over Time in 24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients With Mild Cognitive Impairment (ADCS-MCI-ADL-24) Total Score
Time frame: Baseline, Week 48, Week 96
Change From Baseline Over Time in Repeatable Battery for Assessment of Neuropsychological Status (RBANS) - Total Scale Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Coding Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Digit Span Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Figure Copy Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Figure Recall Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - List Recognition Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - List Learning Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Line Orientation Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - List Recall Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Picture Naming Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Change From Baseline Over Time in RBANS - Semantic Fluency Total Score
Time frame: Baseline, Week 24, Week 48, Week 72, Week 96
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41281734Wang D, Florian H, Lynch SY, Robieson W, Zhuang R, Kusiak C, Ross JL, Walsh JR, Graff O. Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease. Alzheimers Dement (N Y). 2025 Nov 22;11(4):e70181. doi: 10.1002/trc2.70181. eCollection 2025 Oct-Dec.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Related trials for Alzheimer's Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
68 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ABBV-8E12 in people with Alzheimer's Disease, run by AbbVie at 68 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 68 sites in United States, Italy, Australia, Spain, Belgium and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Aug 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline Over Time in CDR-SB Score (time frame: Baseline, Week 24, Week 48, Week 72, Week 96). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02880956, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2022.